THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE

The clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 test...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	resistance to clopidogrel pharmacogenetics cyp2c19
Online Access:	https://www.rpcardio.online/jour/article/view/99
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM
by: Ekaterina S. Kropacheva
Published: (2018-12-01)

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
by: D. A. Sychev, et al.
Published: (2015-09-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01)

The pharmacogenetics antiepileptic drugs
by: N. A. Shnayder, et al.
Published: (2008-12-01)

Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer
by: L. N. Lyubchenko, et al.
Published: (2017-10-01)

Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia
by: Sh. P. Abdullaev, et al.
Published: (2024-05-01)

Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view
by: D. A. Syche, et al.
Published: (2007-08-01)

VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY
by: D. A. Sychev, et al.
Published: (2015-12-01)

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
by: D. A. Sychev, et al.
Published: (2015-09-01)

NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: K. B. Mirzaev, et al.
Published: (2018-03-01)

Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients
by: Ghada S. Rasool, et al.
Published: (2024-01-01)

GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA
by: K. B. Mirzaev, et al.
Published: (2015-10-01)

Progress in pharmacogenetic studies on effect on tacrolimus concentrations
by: YANG Shuang, et al.
Published: (2020-01-01)

PHARMACOGENETIC TESTING OPPORTUNITIES IN CARDIOLOGY BASED ON EXOME SEQUENCING
by: N. V. Shcherbakova, et al.
Published: (2015-09-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
by: Kayla R. Tunehag, et al.
Published: (2025-01-01)

Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment
by: I. I. Temirbulatov, et al.
Published: (2023-10-01)

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy
by: A. A. Muradyan, et al.
Published: (2020-10-01)

Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel
by: O. O. Shakhmatova
Published: (2022-06-01)

Exploring the Pharmacogenetic Landscape: Identification of Clinically Relevant Genotypes by a Nation-Wide Medical Testing Laboratory in Romania
by: Cristina Pop, et al.
Published: (2025-06-01)

PREVALENCE OF POLYMORPHOUS LOCUS 681G>A OF CYP2C19 GENE IN RUSSIAN POPULATION
by: T. A. Bairova, et al.
Published: (2014-11-01)

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
by: R. Rahmatini, et al.
Published: (2018-04-01)

ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)

CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin
by: Rubin Lubomirov, et al.
Published: (2025-04-01)

Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis
by: l. V. Fedina, et al.
Published: (2024-03-01)

EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

The prevalence of CYP2D6*10 (100C>T, rs1065852) gene polymorphism in Russian patients with epilepsy (North-Western and Siberian Districts)
by: N. A. Sivakova, et al.
Published: (2019-12-01)

THE COMPARATIVE EFFICACY OF PERSONALIZING THERAPY WITH ANTICONVULSANTS AND ANTIPSYCHOTICS ON THE BASIS OF PHARMACOGENETIC TESTING
by: T. V. Dokukina, et al.
Published: (2016-08-01)

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population
by: K. B. Mirzaev, et al.
Published: (2019-07-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

Effect of <i>CYP1A2</i>, <i>CYP2D6</i>, and <i>CYP3A4</i> Variation on Antipsychotic Treatment Outcomes
by: Lauren Varney, et al.
Published: (2025-06-01)

Preliminary Data from a Study on Polymorphism RS4244285 of P4502c19 Cytochrome Gene in Patients with Acute Coronary Syndrome, Undergoing Treatment with Dual Antiplatelet Therapy With Clopidogrel and Aspirin
by: Katya Kovacheva, et al.
Published: (2016-09-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023-11-01)

Prevalence of CYP2C19 Variants in Patients with Cardiovascular Disease from the Yunnan-Guizhou Plateau in Southwestern China
by: Li XP, et al.
Published: (2025-05-01)

Frequencies of CYP2C9 polymorphisms in a Syrian cohort
by: Weam Aldiban, et al.
Published: (2025-02-01)

The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome
by: V. Yu. Skryabin, et al.
Published: (2020-01-01)

MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: N. F. Puchinian, et al.
Published: (2017-03-01)